All News
Filter News
Found 808,466 articles
-
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team
3/21/2022
Jasper Therapeutics, Inc. today announced changes to its management team, including the promotions of Jeet Mahal to the newly created position of Chief Operating Officer, and of Wendy Pang, M.D., Ph.D., to Senior Vice President of Research and Translational Medicine.
-
Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters
3/21/2022
Today, the U.S. Food and Drug Administration is announcing a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Wed., April 6, to discuss considerations for future COVID-19 vaccine booster doses and the process for selecting specific strains of the SARS-CoV-2 virus for COVID-19 vaccines to address current and emerging variants.
-
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
3/21/2022
Artelo Biosciences, Inc. today reported financial and operating results for the four month transitional period from September 1, 2021 to December 31, 2021 and provided a business update.
-
Taconic Biosciences Improves rasH2 Carcinogenicity Test System Access in Asia-Pacific RegionFour-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers
3/21/2022
Taconic Biosciences has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively.
-
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
3/21/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an anti-PD1 monoclonal antibody, and its use in cancer treatment.
-
Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
3/21/2022
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting analgesic product CPL-01.
-
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board
3/21/2022
Vivacitas Oncology, Inc. is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier Neuro-Oncology Advisory Board.
-
Archer™ 3D Targeting Planning Software Platform Receives 510(k) Clearance
3/21/2022
Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that the platform technology for its Archer™ 3D Targeting planning software received 510(k) clearance for use in shoulder arthroplasty.
-
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board
3/21/2022
Adhera Therapeutics, Inc. is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board.
-
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
3/21/2022
A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments
-
Mozart Therapeutics Announces Appointment of Jan Beck as Chief Operating Officer
3/21/2022
Mozart Therapeutics today announced the appointment of Jan Beck as Chief Operating Officer.
-
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
3/21/2022
NeuroSense Therapeutics Ltd. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
-
New Study Reveals Strategies for Targeting “Undruggable” KRAS Mutants
3/21/2022
Research published today in Nature Chemical Biology reveals new opportunities for using small molecule drugs to target KRAS, the most commonly mutated protein in cancer.
-
PADAGIS ANNOUNCES THE FDA APPROVAL AND LAUNCH OF AN AB RATED GENERIC VERSION OF TOBRADEX® OPHTHALMIC SUSPENSION
3/21/2022
Padagis today announced the FDA approval and launch of an AB-rated generic version of Tobradex® Ophthalmic Suspension.
-
Ribometrix Promotes Dr. Manjunath Ramarao to Chief Scientific Officer
3/21/2022
Ribometrix announced today the promotion of Manjunath (Manju) Ramarao, Ph.D., to chief scientific officer.
-
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
3/21/2022
Graphite Bio today reported recent business progress and fourth quarter and fiscal year 2021 financial results.
-
Chimeron Bio Enters Into an Agreement With the NIAID, a Federal Agency, for Pre-clinical Assessment of Its Self-Amplifying COVID-19 Vaccine
3/21/2022
Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM RNA delivery platform, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the potential of its vaccine for COVID-19.
-
Noblis Awarded Patent for Primer Design Using Indexed Genomic Information
3/21/2022
Noblis, Inc., a leading provider of science, technology and strategy services to the federal government, announced the award of U.S. patent 11,222,712 for primer design using indexed genomic information.
-
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
3/21/2022
Chinook Therapeutics, Inc. today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors.
-
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
3/21/2022
UroGen Pharma Ltd. today announced financial results for the fourth quarter and full year ended December 31, 2021, and overview of recent developments.